// App-Quantinova.ai

TCT-35 : Evaluation of the Absorb Everolimus Eluting Bioresorbable Vascular Scaffold (Absorb BVS) in the Treatment of Patients with de Novo Native Coronary Artery Lesions: 3 Year Clinical Results of the ABSORB Cohort B1 Trial

Researchers

Presenter

  • Peter Smits

Principal Investigators

  • N/A

Medical Centers

  • N/A

Locations

  • N/A

Companies

  • N/A

Study Components

Therapeutic Area

  • Cardiovascular (CVS)

Disease

  • Coronary artery lesions

  • Hypercholesterolemia, Familial, 1

  • Angina

  • Hypertension

  • Venous thrombosis

  • Coronary Artery Disease

  • Diabetes

Biomarkers

  • Acetyl-CoA carboxylase

Drug/Treatment

  • Everolimus

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved